Recruiting · registry status

Medicines, mood and motivation

This study uses supervised medicine and placebo sessions to investigate reward-related thinking in Parkinson's.

Testing a treatment or activity · Study reference: NL-OMON27566

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Results reported

Start (reported date): 2007-12-01

Planned dates can move. A study finishing does not tell us when a paper will be published.

Read the results reported in the registry

Changes we have recorded

2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Age range not listed · Ask the team who can join

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: Not reported

Inclusion criteria: 1. Idopathic Parkinson's disease; 2. Informed consent. Exclusion criteria: 1. Other concurrent neurological diseases than PD; 2. Concurrent psychiatric disease; 3. Use of psychopharmacological medication; 4. Abuse of alcohol and drugs; 5. Cognitive deterioration as operationalized by a score of <23 on the MMSE; 6. Use of levodopa preparations of dopamine agonists.

Full study name & original research details

Official study title

Reward mechanisms, mood and motivational symptoms in Parkinson's disease: an experimental approach.

Original description

Intervention: All subjects receive a 10 mg methylphenidate challenge, a 500 ìg pramipexole challenge and a placebo condition. Primary outcome: Main study parameters are the performance on neuropsychiatric and neuropsychological tests for both groups, including assessments of cognitive status, mood, apathy, and an observation of spontaneous self-reward behaviour.

Conditions reported: Parkinson's disease (NLD: De ziekte van Parkinson).

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

NL-OMON · NL-OMON27566 ↗ — Recruiting; WHO ICTRP processed 2024-02-28; checked 2026-10-11

Study type: Interventional
Interventions: All subjects receive a 10 mg methylphenidate challenge, a 500 ìg pramipexole challenge and a placebo condition.
Phases: Not reported
Sponsor: Maastricht University
Start date reported by registry: 2007-12-01 (reported)

Registry updated: Not reported · Status last verified by the registry submitter: Not reported

Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

R.L. Drijgers · 043-3881839 · rosa.drijgers@np.unimaa

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

No locations reported. Ask the study team where participation is available.

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.